Off-label uses of denosumab in metabolic bone diseases
Bone. 2019 Dec;129:115048. doi:10.1016/j.bone.2019.115048 Polyzos SA, Makras P, Tournis S, Anastasilakis AD
In-vitro comparison of hydroxyapatite coatings obtained by cold spray and conventional thermal spray technologies
In-vitro comparison of hydroxyapatite coatings obtained by cold spray and conventional thermal spray technologies
Osteopenia and Osteoporosis in Patients with Bronchiectasis: Association with Respiratory Parameters, Body Composition, Muscle Strength and Bone Remodeling Biomarkers.
Osteopenia and Osteoporosis in Patients with Bronchiectasis: Association with Respiratory Parameters, Body Composition, Muscle Strength and Bone Remodeling Biomarkers.
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
Cholecalciferol and calcifediol for vitamin D supplementation.
Cholecalciferol and calcifediol for vitamin D supplementation.
Analysis of bone impairment by 3D DXA hip measures in patients with primary hyperparathyroidism: a pilot study.
Analysis of bone impairment by 3D DXA hip measures in patients with primary hyperparathyroidism: a pilot study.
Long term effects on biochemical bone markers of a single infusion of zoledronic acid in Paget disease of bone.
Long term effects on biochemical bone markers of a single infusion of zoledronic acid in Paget disease of bone.
Ten years change in post-fracture care for hip fracture patients.
Ten years change in post-fracture care for hip fracture patients.
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
